Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential diagnosis of suspected multiple sclerosis: global health considerations.
Correale J, Solomon AJ, Cohen JA, Banwell BL, Gracia F, Gyang TV, de Bedoya FHD, Harnegie MP, Hemmer B, Jacob A, Kim HJ, Marrie RA, Mateen FJ, Newsome SD, Pandit L, Prayoonwiwat N, Sahraian MA, Sato DK, Saylor D, Shi FD, Siva A, Tan K, Viswanathan S, Wattjes MP, Weinshenker B, Yamout B, Fujihara K. Correale J, et al. Among authors: marrie ra. Lancet Neurol. 2024 Oct;23(10):1035-1049. doi: 10.1016/S1474-4422(24)00256-4. Lancet Neurol. 2024. PMID: 39304243 Review.
Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A Review.
Hua LH, Solomon AJ, Tenembaum S, Scalfari A, Rovira À, Rostasy K, Newsome SD, Marrie RA, Magyari M, Kantarci O, Hemmer B, Hemingway C, Harnegie MP, Graves JS, Cohen JA, Bove R, Banwell B, Corboy JR, Waubant E. Hua LH, et al. Among authors: marrie ra. JAMA Neurol. 2024 Sep 16. doi: 10.1001/jamaneurol.2024.3062. Online ahead of print. JAMA Neurol. 2024. PMID: 39283621
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia.
Amezcua L, Rotstein D, Shirani A, Ciccarelli O, Ontaneda D, Magyari M, Rivera V, Kimbrough D, Dobson R, Taylor B, Williams M, Marrie RA, Banwell B, Hemmer B, Newsome SD, Cohen JA, Solomon AJ, Royal W 3rd. Amezcua L, et al. Among authors: marrie ra. Lancet Neurol. 2024 Oct;23(10):1050-1062. doi: 10.1016/S1474-4422(24)00288-6. Lancet Neurol. 2024. PMID: 39304244 Review.
2010 McDonald criteria for diagnosing pediatric multiple sclerosis.
Sadaka Y, Verhey LH, Shroff MM, Branson HM, Arnold DL, Narayanan S, Sled JG, Bar-Or A, Sadovnick AD, McGowan M, Marrie RA, Banwell B; Canadian Pediatric Demyelinating Disease Network. Sadaka Y, et al. Among authors: marrie ra. Ann Neurol. 2012 Aug;72(2):211-23. doi: 10.1002/ana.23575. Ann Neurol. 2012. PMID: 22926854
Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis.
Kowalec K, Harder A, Dolovich C, Fitzgerald KC, Salter A, Lu Y, Bernstein CN, Bolton JM, Cutter G, Fisk JD, Gelernter J, Graff LA, Hägg S, Hitchon CA, Levey DF, Lublin FD, McKay KA, Patten S, Patki A, Stein MB, Tiwari HK, Wolinsky JS, Marrie RA. Kowalec K, et al. Among authors: marrie ra. Ann Clin Transl Neurol. 2024 Jun;11(6):1393-1404. doi: 10.1002/acn3.52025. Epub 2024 May 7. Ann Clin Transl Neurol. 2024. PMID: 38715244 Free PMC article.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. O'Connor P, et al. Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Neurology. 2016. PMID: 26865517 Free PMC article. Clinical Trial.
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. Uccelli A, et al. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z. Trials. 2019. PMID: 31072380 Free PMC article.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
535 results